<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10098759</article-id><article-id pub-id-type="pmc">2362245</article-id><article-id pub-id-type="pii">6690192</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bouffet</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref rid="note1" ref-type="fn"/></contrib><contrib contrib-type="author"><name><surname>Baranzelli</surname><given-names>M C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Patte</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Portas</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Edan</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Chastagner</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Mechinaud-Lacroix</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kalifa</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><collab>on behalf of the Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise d'Oncologie P&#x000e9;diatrique</collab></contrib><aff id="aff1">Service d'Oncologie P&#x000e9;diatrique, Centre L B&#x000e9;rard, 28 rue Laennec, Lyon C&#x000e9;dex, 69008, France</aff><aff id="aff2">Service d'Oncologie M&#x000e9;dicale &#x0003c;A&#x0003e;, Centre O Lambret, 3 rue F Combemale, Lille C&#x000e9;dex, 59020, France</aff><aff id="aff3">Service de P&#x000e9;diatrie, Institut Gustave Roussy, 39 rue C Desmoulins, Villejuif C&#x000e9;dex, 94805, France</aff><aff id="aff4">Service d'Oncologie P&#x000e9;diatrique, H&#x000f4;pital d'Enfants de la Timone, Marseille C&#x000e9;dex, 13385, France</aff><aff id="aff5">Clinique M&#x000e9;dicale Infantile, CHR, 16 rue de Bulgarie, Rennes C&#x000e9;dex, 35056, France</aff><aff id="aff6">Service de M&#x000e9;decine Infantile II, H&#x000f4;pital d'Enfants, Vandoeuvre, France</aff><aff id="aff7">Service d'Oncologie P&#x000e9;diatrique, CHR, Nantes C&#x000e9;dex, 44035, France</aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>Service d'Oncologie M&#x000e9;dicale &#x0003c;A&#x0003e;, Centre O Lambret, 3 rue F Combemale, 59020 Lille C&#x000e9;dex, France</corresp><fn fn-type="present-address" id="note1"><p>Present address: Department of Paediatric Oncology, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>1999</year></pub-date><volume>79</volume><issue>7-8</issue><fpage>1199</fpage><lpage>1204</lpage><history><date date-type="received"><day>02</day><month>03</month><year>1998</year></date><date date-type="rev-recd"><day>13</day><month>07</month><year>1998</year></date><date date-type="accepted"><day>03</day><month>08</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Conventional therapy for intracranial germinomas is craniospinal irradiation. In 1990, the Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise d'Oncologie P&#x000e9;diatrique initiated a study combining chemotherapy (alternating courses of etoposide&#x02013;carboplatin and etoposide&#x02013;ifosfamide for a recommended total of four courses) with 40 Gy local irradiation for patients with localized germinomas. Metastatic patients were allocated to receive low-dose craniospinal radiotherapy. Fifty-seven patients were enrolled between 1990 and 1996. Forty-seven had biopsy-proven germinoma. Biopsy was not performed in ten patients (four had diagnostic tumour markers and in six the neurosurgeon felt biopsy was contraindicated). Fifty-one patients had localized disease, and six leptomeningeal dissemination. Seven patients had bifocal tumour. All but one patient received at least four courses of chemotherapy. Toxicity was mainly haematological. Patients with diabetus insipidus (<italic>n</italic> = 25) commonly developed electrolyte disturbances during chemotherapy. No patient developed tumour progression during chemotherapy. Fifty patients received local radiotherapy with a median dose of 40 Gy to the initial tumour volume. Six metastatic patients, and one patient with localized disease who stopped chemotherapy due to severe toxicity, received craniospinal radiotherapy. The median follow-up for the group was 42 months. Four patients relapsed 9, 10, 38 and 57 months after diagnosis. Three achieved second complete remission following salvage treatment with chemotherapy alone or chemo-radiotherapy. The estimated 3-year survival probability is 98&#x00025; (CI: 86.6&#x02013;99.7&#x00025;) and the estimated 3-year event-free survival is 96.4&#x00025; (CI: 86.2&#x02013;99.1&#x00025;). This study shows that excellent survival rates can be achieved by combining chemotherapy and local radiotherapy in patients with non-metastatic intracranial germinomas. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>germinoma</kwd><kwd>tumour markers</kwd><kwd>chemotherapy</kwd><kwd>local irradiation</kwd><kwd>bifocal tumour</kwd></kwd-group></article-meta></front></article>
